JPRN-UMIN000016137
Completed
未知
Phase I study of safety of morphine for dyspnea in patients with interstitial lung disease - Phase I study of safety of morphine for dyspnea in patients with interstitial lung disease
on-Profit Organization JORTC0 sites12 target enrollmentJanuary 6, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Dyspnea in patients with interstitial lung disease
- Sponsor
- on-Profit Organization JORTC
- Enrollment
- 12
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients with contraindication of morphine (ex. allergy for morphine and history of severe adverse effects of morphine) 2\. Patients who use opioid 3\. Patients with left heart failure by echocardiography. 4\. Patients with acute respiratory failure ( bacterial pneumonia, acute excerbation of interstitial pneumonia and so on). 5\. Patients with active infection that causes dyspnea 6\. Patients with lung cancer that causes dyspnea 7\. Patients with pneumothorax 8\. Patients who uses invasive positive airway pressure ventilation. Patients who uses nasal high flow were not excluded 9\. Patients who changed the way of intaking of corticosteroids, immunosuppressant, bronchodilators, vasodilators and anxiolytics within two days before enrollment of the study 10\. Patients who have or had drug abuse or drug dependence 11\. Patients who are pregnant or possibly pregnant 12\. Patients who are judged to be innapropriate for the study by the physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Morphine for dysnea in patients with lung fibrosisInterstitial Lung diseaseTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2015-002533-22-DKAarhus University Hospital36
Recruiting
Phase 2
The effect of morphine with nebulizer mask in the treatment of acute respiratory distress in adult patients with Covid-19IRCT20211112053042N2Karaj University of Medical Sciences60
Active, not recruiting
Phase 1
Palliation of Dyspnea and Cough using Morphine in patients with Fibrotic Interstitial Lung DiseaseFibrotic Interstitial Lung DiseaseMedDRA version: 21.1Level: PTClassification code: 10022611Term: Interstitial lung disease Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]CTIS2023-503700-81-00Aarhus University Hospital110
Completed
Not Applicable
Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary diseaseJPRN-UMIN000015288on-Profit Organization JORTC35
Unknown
Phase 3
Morphine for Dyspnea in Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)NCT04497831Medical University of Gdansk20